Radiolabeling of zoledronic acid with 188Re as a new palliative agent radiotracer in treatment of bone tumors
- 69 Downloads
Zoledronic acid is a bisphosphonates to treat bone problems. Rhenium-188-zoledronic acid could be used as a palliate agent in skeletal metastases. Radiolabeled product was prepared through optimized radiochemical procedures. The organs uptake especially bone uptake assessed in healthy animals mice. The radiochemical purity of the radiotracer was > 95% which was stable up to 24 h. Bone uptake (1.08 ± 0.14% ID/g at 1 h) with retention of activity in bone up to 24 h (0.26 ± 0.06% ID/g) was reached. This radiotracer can be used as a developing candidate for a palliative treatment of bone metastasis.
Keywords188Re-ZNA Zolendronic acid Radiotracer Palliative Skeletal metastases
We like to appreciate Mr. Pezham for providing sodium perrehenate and help through animal study.
- 1.Vincent J, Vigorita MD (2007) Cancer-principles and practice of oncology. Lippincott, Williams & Wilkins, Philadelphia, pp 2713–2729Google Scholar
- 11.Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B (2004) Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15(5):743–750CrossRefGoogle Scholar
- 13.Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321CrossRefGoogle Scholar
- 14.Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron DW (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92(10):1869–1876CrossRefGoogle Scholar
- 15.Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387Google Scholar
- 17.Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 5ALSYMPCA6 trial. Lancet Oncol 15(12):1397–1406CrossRefGoogle Scholar
- 19.Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365Google Scholar
- 28.Kochetova T, Krylov V, Smolyarchuk M, Sokov D, Lunev A, Shiryaev S, Kruglova O, Makeenkova T, Petrosyan K, Dolgova A, Poluektova M, Galkin V, Kaprin A (2017) 188Re zoledronic acid in the palliative treatment of painful bone metastases. Int J Nucl Medi Res. https://doi.org/10.15379/2408-9788.2017.08 Google Scholar
- 30.Janoki GA, Polyak A, Kiraly R, Balogh L, Korosi L, Mathe D (2007) Comparative evaluation of therapeutic radiopharmaceuticals. International Atomic Energy Agency, ViennaGoogle Scholar
- 31.Erfani M, Doroudi A, Dinari MA, Shirmardi SP (2015) Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy. J Radioanal Nucl Chem 303:2027–2032Google Scholar
- 32.Stenbeck G, Horton MA (2000) A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci 13:1577–1587Google Scholar